Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02487147 · ClinicalTrials.gov registry record · NA
Evaluation of Free Air Portable Air Powered Respirator
A NA study of Influenza, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- NA
- Development phase
- 58
- Enrollment target
- 1
- Study location
NCT02487147: Completed NA study of Influenza, sponsored by Wake Forest University Health Sciences.
NCT02487147 is a NA study of Influenza that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 58 participants, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02487147, a NA study of Influenza, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- NA
- Development phase
- 58 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will compare the efficacy of the Free Air Portable Air Powered Respirator (PAPR) system versus a N95 mask in preventing nasal detection of influenza following an exposure. The investigators hypothesize the use of the Free Air PAPR system will be superior to a N95 respirator at interrupting the exposure of the study participants to aerosolized influenza virus particles.
Primary Outcome
A nasal swab will be performed immediately following the exposure.
Conditions Studied
Interventions
- OTHER N95 Respirator
- OTHER Free Air Portable Air Powered Respirator
Study Locations (1)
North Carolina
- Wake Forest School Of Medicine - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2016-11-14 |
| Est. Completion | 2016-12-12 |
| Phase | NA |
What the finished NCT02487147 record still lists
NCT02487147 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 36,804-participant average among 156 other Influenza trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Influenza appearing as the primary indexed condition, and to 2 interventions - of which N95 Respirator is the first listed.
NCT02487147 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02487147 about?
NCT02487147 is a clinical study titled "Evaluation of Free Air Portable Air Powered Respirator". This study will compare the efficacy of the Free Air Portable Air Powered Respirator (PAPR) system versus a N95 mask in preventing nasal detection of influenza following an exposure. The investigators hypothesize the use of the Free Air PAPR system will be superior to a N95 respirator at interruptin...
What is the current status of trial NCT02487147?
This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2016-11-14. Estimated completion is 2016-12-12.
What conditions does trial NCT02487147 study?
This clinical trial studies the following conditions: Influenza.
What interventions are being tested in trial NCT02487147?
The interventions under investigation include: N95 Respirator (OTHER), Free Air Portable Air Powered Respirator (OTHER).
Who is sponsoring clinical trial NCT02487147?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02487147 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Influenza
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02487147's enrollment target sits among peer trials
58 123rd of 156 higher than 34 of 156 other Influenza trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Influenza trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Influenza Immunization in Adults Over Age 75
RECRUITING · NA
-
H5N1 Milk Detection Study
RECRUITING · NA
-
Immune Defense Protein Impact On Respiratory Immune Outcomes
RECRUITING · NA
-
Dime La VerDAD: Verify, Debunk, and Disseminate
RECRUITING · NA
-
The INFLUENTIAL Trial- Evaluation of National Inpatient Influenza Vaccination Program
RECRUITING · NA
-
Impact of High Dietary Fiber on Microbiome and Vaccine Responses
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03587844 · 58 participants · Phase 2
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
- NCT03630991 · 58 participants · Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
- NCT03949855 · 58 participants · Phase 2
Belimumab With Rituximab for Primary Membranous Nephropathy
- NCT04069273 · 58 participants · Phase 2
Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI